YBX1 and myeloproliferative disorder: Given the disease-driving role of megakaryocytes in MPNs [18–23], these studies collectively suggest targeting YBX1 function may selectively antagonize megakaryocyte over erythroid development in MPN patients, and importantly, potentially spare healthy megakaryocyte development.